Loading
Cardio Renal Vascular Function and Failure / T1D Heart Failure / Finerenone · Phase 2 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 2 trial not yet recruiting, designed to test finerenone and sotagliflozin in people with type 1 diabetes and cardio-renal complications. The study is hypothesis-generating, aiming to match disease endophenotypes to targeted drug candidates; no outcomes have been reported in this registry record.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease; age from 18 Years; to 75 Years. Intervention: Finerenone; Sotagliflozin. n = 57. 2 sites: United States.
This is a registered Phase 2 trial not yet recruiting, designed to test finerenone and sotagliflozin in people with type 1 diabetes and cardio-renal complications. The study is hypothesis-generating, aiming to match disease endophenotypes to targeted drug candidates; no outcomes have been reported in this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
No clinical impact can be assessed; this is a registered trial in recruitment phase. Results when available will inform safety and tolerability of finerenone and sotagliflozin in T1D cardio-renal disease and may guide future mechanism-targeted therapy selection.
A Phase 2 interventional trial registered but not yet recruiting, with safety and tolerability as primary outcomes in a small planned cohort; no results are posted.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed; this is a registered trial in recruitment phase. Results when available will inform safety and tolerability of finerenone and sotagliflozin in T1D cardio-renal disease and may guide future mechanism-targeted therapy selection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07594145). This is a study registration, not published results. Lead sponsor: Oregon Health and Science University. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 57 participants (ESTIMATED). Conditions: Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease. Interventions: DRUG: Finerenone; DRUG: Sotagliflozin. Primary outcome measures: Markers of Renal Health [Safety and Tolerability] , 26 weeks; Markes of Cardio Health [Safety and Tolerability] , 26 weeks; Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] , 26 weeks. Brief summary: Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.